Oryzon Genomics developed ORY-1001 in 2012, which uses TCP as the lead compound and is currently being studied in clinical trials for AML and SCLC (NCT05546580 and NCT02913443).1352 INCB059872, an irreversible LSD1 inhibitor reported by Lee et al. in 2016, has undergone five clinical trials to test its safety and efficacy in treating solid tumors and hematologic malignancies (NCT02712905, NCT02959437, NCT03132324, NCT03514407, and NCT04061421). Here, KDM1A is linked to small cell lung carcinoma.